WO2002059607A3 - Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan - Google Patents

Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan Download PDF

Info

Publication number
WO2002059607A3
WO2002059607A3 PCT/GB2002/000034 GB0200034W WO02059607A3 WO 2002059607 A3 WO2002059607 A3 WO 2002059607A3 GB 0200034 W GB0200034 W GB 0200034W WO 02059607 A3 WO02059607 A3 WO 02059607A3
Authority
WO
WIPO (PCT)
Prior art keywords
epidermal stem
stem cells
melanoma
isolation
chondroitin sulfate
Prior art date
Application number
PCT/GB2002/000034
Other languages
French (fr)
Other versions
WO2002059607A2 (en
Inventor
Anthony Gerard Quinn
Nicholas Tidman
Original Assignee
Cancer Rec Tech Ltd
Anthony Gerard Quinn
Nicholas Tidman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Anthony Gerard Quinn, Nicholas Tidman filed Critical Cancer Rec Tech Ltd
Priority to AU2002216296A priority Critical patent/AU2002216296A1/en
Publication of WO2002059607A2 publication Critical patent/WO2002059607A2/en
Publication of WO2002059607A3 publication Critical patent/WO2002059607A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides methods for isolating and identifying epidermal stem cells, and uses thereof. Methods for enriching a population of cells for epidermal stem cells are provided. The methods make use of the MCSP protein. An epidermal stem cell specific promoter and an epidermal stem cell specific delivery vehicle and uses thereof are also described.
PCT/GB2002/000034 2001-01-04 2002-01-04 Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan WO2002059607A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002216296A AU2002216296A1 (en) 2001-01-04 2002-01-04 Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25977001P 2001-01-04 2001-01-04
US60/259,770 2001-01-04

Publications (2)

Publication Number Publication Date
WO2002059607A2 WO2002059607A2 (en) 2002-08-01
WO2002059607A3 true WO2002059607A3 (en) 2003-10-30

Family

ID=22986299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000034 WO2002059607A2 (en) 2001-01-04 2002-01-04 Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan

Country Status (2)

Country Link
AU (1) AU2002216296A1 (en)
WO (1) WO2002059607A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938587A (en) * 2020-01-08 2020-03-31 济南磐升生物技术有限公司 Preparation method and application of epidermal stem cell suspension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
WO1997013855A1 (en) * 1995-10-10 1997-04-17 Novartis Ag Melanoma-associated protein
WO1999047644A1 (en) * 1998-03-18 1999-09-23 Peter Maccallum Cancer Institute Keratinocyte stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
WO1997013855A1 (en) * 1995-10-10 1997-04-17 Novartis Ag Melanoma-associated protein
WO1999047644A1 (en) * 1998-03-18 1999-09-23 Peter Maccallum Cancer Institute Keratinocyte stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEISER M ET AL: "Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library.", CANCER RESEARCH. UNITED STATES 15 FEB 1999, vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 905 - 910, XP002240701, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2002059607A2 (en) 2002-08-01
AU2002216296A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
AU9231998A (en) Antigen presenting mesenchymal stem cells
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU2003226608A1 (en) Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
WO2001039722A3 (en) B7-h1, a novel immunoregulatory molecule
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2002077264A3 (en) Arrayed transfection method and uses related thereto
AU2001286202A1 (en) Method of culturing mesenchymal stem cells
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
WO2000046585A3 (en) Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose
WO2003024406A3 (en) Nestin-expressing hair follicle stem cells
WO2003003004A3 (en) Method for identifying compounds the specifically deplete mast cells
AU2002306865A1 (en) Generation of multipotent central nervous system stem cells
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
AU1741601A (en) Mesenchymal stem cells and/or progenitor cells, their isolation and use
EP0821064A3 (en) Recombinant fructosyl amino acid oxidase
AU2003238717A1 (en) POLYPEPTIDES HAVING Alpha- H-Alpha-AMINO ACID AMIDE RACEMASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
WO1996002650A3 (en) Dna, constructs, cells and plants derived therefrom
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2001072970A3 (en) Methods to prepare and use epidermal stem cells
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
WO2002059607A3 (en) Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan
AU2002328803A1 (en) Marker for identifying hematopoietic stem cells
WO2003004616A3 (en) Dendritic cell isolation methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP